Learn about Research & Clinical Trials

Autologous Lung Stem Cell Transplantation in Patients With Interstitial Lung Diseases

Study Purpose

Interstitial lung diseases (ILD) are a group of diseases affecting the lung interstitium. The lung scarring that occurs in ILD is often irreversible with only mitigating therapy available so far. This study intends to carry out an open, single-armed, phase I/II clinical trial to investigate whether lung stem cells can regenerate damaged lung tissue. During the treatment, lung stem cells will be isolated from patients' own bronchi and expanded in vitro. After careful characterization, cultured cells will be injected directly into the lesion by fiberoptic bronchoscopy. The safety and efficacy of the treatment will be monitored by measuring the key clinical indicators.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 20 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Diagnosed with interstitial lung disease.
  • - Clinically stable.
  • - Written informed consent signed.

Exclusion Criteria:

  • - Allergic to cell therapy; - Patients with serious significant pulmonary infection need anti-infection treatment; - Patients who has taken amiodarone which may cause pulmonary fibrosis in the past 3 months; - Patients with malignant tumor in the past 5 years; - Participated in other clinical trials in the past 3 months; - Patients with serious heart disease(NYHA class Ⅲ-Ⅳ) - Pregnant or lactating women; - The investigator assessed as inappropriate to participate in this clinical trial.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Shanghai East Hospital
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other, Industry
Overall Status Recruiting
Countries China

The disease, disorder, syndrome, illness, or injury that is being studied.

Interstitial Lung Diseases
Arms & Interventions


Experimental: lung stem cells

Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.


Biological: - Lung stem cells

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Regend Therapeutics, Suzhou, Jiangsu, China




Regend Therapeutics

Suzhou, Jiangsu, 215123

Site Contact

Wei Zuo, Ph.D.


Shanghai East Hospital, Shanghai, Shanghai, China




Shanghai East Hospital

Shanghai, Shanghai, 200123

Site Contact

Tao Ren, M.D.